Drs. Bossi, Wallis on the Synergistic Effects of Abiraterone, Radiotherapy for De Novo mCSPC

Alberto Bossi, MD, Gustave Roussy Cancer Institute, and Christopher Wallis, MD, PhD, University of Toronto, continue their discussion on the PEACE-1 study with a commentary on whether all patients with de novo mCSPC experience synergistic effects on treatment with abiraterone plus radiotherapy.

In the first part of this video series, Drs. Bossi and Wallis detailed the design and results of the PEACE-1 study presented as a late-breaking abstract at the ASCO Annual Meeting.

View their other discussions on Prostate Irradiation in Men With De Novo, Low-Volume mCSPC and the Right Patients for Radiotherapy When Presenting With De Novo mCSPC.